CA2604933C - Methods and compositions for modulating and detecting wisp activity - Google Patents

Methods and compositions for modulating and detecting wisp activity Download PDF

Info

Publication number
CA2604933C
CA2604933C CA2604933A CA2604933A CA2604933C CA 2604933 C CA2604933 C CA 2604933C CA 2604933 A CA2604933 A CA 2604933A CA 2604933 A CA2604933 A CA 2604933A CA 2604933 C CA2604933 C CA 2604933C
Authority
CA
Canada
Prior art keywords
wisp
cells
domain
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2604933A
Other languages
English (en)
French (fr)
Other versions
CA2604933A1 (en
Inventor
Luc Desnoyers
Ellen Filvaroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2604933A1 publication Critical patent/CA2604933A1/en
Application granted granted Critical
Publication of CA2604933C publication Critical patent/CA2604933C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2604933A 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity Expired - Fee Related CA2604933C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/105,876 2005-04-14
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (2)

Publication Number Publication Date
CA2604933A1 CA2604933A1 (en) 2006-10-26
CA2604933C true CA2604933C (en) 2014-07-08

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2604933A Expired - Fee Related CA2604933C (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Country Status (16)

Country Link
US (2) US7455834B2 (enExample)
EP (1) EP1869086B1 (enExample)
JP (1) JP4979684B2 (enExample)
KR (1) KR101320261B1 (enExample)
CN (1) CN101198623B (enExample)
AU (1) AU2006236649B2 (enExample)
BR (1) BRPI0612184A8 (enExample)
CA (1) CA2604933C (enExample)
ES (1) ES2388993T3 (enExample)
IL (1) IL186095A (enExample)
MX (1) MX2007012798A (enExample)
NO (1) NO20075825L (enExample)
NZ (1) NZ561709A (enExample)
RU (1) RU2412201C2 (enExample)
WO (1) WO2006113402A1 (enExample)
ZA (1) ZA200708738B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
EP2978454A1 (en) * 2013-03-27 2016-02-03 Ge Healthcare As Method and reagent for preparing a diagnostic composition
AU2015247742A1 (en) * 2014-04-15 2016-11-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
JP7264382B2 (ja) * 2018-05-17 2023-04-25 オリーブス バイオセラピューティクス インコーポレイテッド 網膜疾患を予防又は治療するための、有効成分としてｃｃｎ５を含む医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP2003533164A (ja) 1997-10-29 2003-11-11 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導分泌ポリペプチド：ＷＩＳＰ−１，−２及び−３
PT1623990E (pt) 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US7456262B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and composition for modulating and detecting wisp activity
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
WO2005025603A2 (en) 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists

Also Published As

Publication number Publication date
NO20075825L (no) 2008-01-11
US20090148448A1 (en) 2009-06-11
EP1869086A1 (en) 2007-12-26
IL186095A (en) 2012-10-31
HK1112470A1 (en) 2008-09-05
CA2604933A1 (en) 2006-10-26
MX2007012798A (es) 2007-11-20
KR101320261B1 (ko) 2013-10-22
ZA200708738B (en) 2009-01-28
US7455834B2 (en) 2008-11-25
NZ561709A (en) 2009-12-24
CN101198623A (zh) 2008-06-11
WO2006113402A1 (en) 2006-10-26
AU2006236649B2 (en) 2012-03-29
AU2006236649A1 (en) 2006-10-26
BRPI0612184A2 (pt) 2011-12-20
BRPI0612184A8 (pt) 2017-12-26
RU2007142005A (ru) 2009-05-20
RU2412201C2 (ru) 2011-02-20
IL186095A0 (en) 2008-01-20
CN101198623B (zh) 2013-06-12
KR20080003344A (ko) 2008-01-07
AU2006236649A2 (en) 2008-07-24
EP1869086B1 (en) 2012-07-18
US7732567B2 (en) 2010-06-08
ES2388993T3 (es) 2012-10-22
JP2008537958A (ja) 2008-10-02
JP4979684B2 (ja) 2012-07-18
US20060147453A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
EP1853312A2 (en) Methods and compositions for modulating tweak and fn14 activity
CA2489515C (en) Methods and compositions for modulating and detecting wisp activity
AU2004272066B2 (en) Methods of using WISP antagonists
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity
US20110159588A1 (en) Methods for Modulating a PDGF-AA Mediated Biological Response

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190415